This article is more than 5 years old. Information may no longer be current.

Clinical trial results for oral insulin show promise

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Oramed Pharmaceuticals Inc. recently announced positive clinical results from its phase 2a clinical trial of ORMD-0801, oral insulin capsules, to treat type 1 diabetes, according to a press release.

The safety and effectiveness of ORMD-0801 given before meals were evaluated by a prospective, randomized, double blind, placebo-controlled trial among 25 patients with type 1 diabetes. Results indicated that oral insulin was safe and well tolerated for the dosing regimen in the study.

“We are very pleased with the outcome of this study and look forward to sharing it with the scientific community,” Miriam Kidron, PhD, chief scientific officer of Oramed, said in the release. “We continue to build our body of human clinical data in support of the use of ORMD-0801 to treat both type 1 and type 2 diabetes. With the data gathered so far, we look forward to initiating our phase 2b study of ORMD-0801 in type 2 diabetes patients later this year.”